Doctors are increasingly alarmed that a type of dementia which closely resembles Alzheimer's may have resulted in the ...

First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation ...

In the last few years, progress has been made in the fight against Alzheimer's disease with a class of therapies called anti-amyloid antibodies (anti-Aβ). These monoclonal anti-Aβs are proteins made ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new ...

For the millions of Americans touched by Alzheimer’s disease, 2025 brought major advances in understanding of brain health and progress in diagnosis and treatment. Here are the year’s biggest ...

An autoinjector to administer Leqembi to patients with early-stage Alzheimer’s disease had high degrees of satisfaction for utility, feasibility and convenience for use at home, according to a poster.

Biogen Inc.‘s (NASDAQ: BIIB) partner Eisai Co., Ltd, on Friday filed a new drug application for Leqembi (lecanemab) seeking approval for a subcutaneous formulation (SC-AI) as a new route of ...

TOKYO and CAMBRIDGE, Mass., Nov. 27, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB ...

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this ...